Policy Digest — May 11, 2026

Weekly Spotlight

FDA in Flux: Makary’s Likely Exit, the Voucher Fight, and a Modernization Push Mid-Transition

On Friday May 8 the White House signed off on a plan to fire Food and Drug Administration (FDA) Commissioner Marty Makary, capping a tumultuous year. Politico reports the precipitating event was Trump’s demand that Makary clear fruit-flavored vapes following a meeting with an R.J. Reynolds representative. Makary had also clashed with Department of Health and Human Services (HHS) Chief Counselor and Medicare Director Chris Klomp over personnel and policy. STAT and the New York Times confirmed the reporting and noted his agenda on review timelines, misleading drug ads, and food-chemical phaseouts.

The backdrop is the Commissioner’s National Priority Review Voucher (CNPV) program, which became a flashpoint over political interference in drug review. Sanofi asked to pull teplizumab (Tzield) from the program after acting Center for Drug Evaluation and Research (CDER) Director Tracy Beth Høeg disagreed with a staff approval decision and the agency missed its April 21 goal date. Rep. Jake Auchincloss (D-MA) called the program illegal and warned of political pressure on review timelines. Friday’s Bizengri (zenocutuzumab) approval for NRG1-fusion cholangiocarcinoma became the seventh and probably last CNPV grant under Makary.

Modernization announcements continued in parallel. FDA released Elsa 4.0 on May 4, an internal large language model with custom AI agents and secure internet search. On May 6 the agency launched a one-day inspection pilot for domestic and overseas manufacturing facilities flagged as low-risk by AI tools, with Becker’s framing the move as the agency doing more with less after workforce cuts strained inspectional capacity. MedPage Today read the pattern as heavy on media announcements and light on formal rulemaking.

For device makers, the implications are indirect but real. Leadership turnover affects review timing and roadmap predictability. The CNPV episode signals the political dimension of review prioritization, relevant to anyone navigating FDA pathways for novel products. AI-driven inspection prioritization changes how manufacturing oversight is allocated. Devices were not named in this week’s turbulence, but the regulatory environment around them is being remade.

Forward-looking: Makary is scheduled to testify before Senate Appropriations on May 13 and is likely to face questions on CNPV, review capacity, and leadership turnover. Succession and the durability of the modernization push are open. STAT’s interviews with six former FDA officials, including former CDER Director Richard Pazdur, offer a window into agency morale a year after DOGE-era staff cuts.

Tags: #DEVICE #DRUG

Centers for Medicare and Medicaid Services (CMS)

Medicare’s RAPID coverage pathway in focus: CDRH MDUFA VI signals and pediatric coverage gaps

FDA Center for Devices and Radiological Health leadership teased forthcoming MDUFA VI, RAPID, and interoperability work at a recent appearance, signaling continued institutional focus on the pathway. Separately, STAT published an opinion arguing the Medicare RAPID coverage pathway represents a breakthrough for adults but leaves children behind, citing gaps in pediatric device coverage policy.

• CDRH Leader Teases MDUFA VI, RAPID, Interoperability Paper
• Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting

Tags: #DEVICE #PROVIDER #PATIENT

States and hospitals brace for Medicaid work requirements implementation

Multiple voices this week unpacked the looming implementation of Medicaid work reporting requirements under the One Big Beautiful Bill Act. State surveys, hospital playbooks, MACPAC oversight guidance, and Georgetown analysis all converged on the same theme: states and providers are scrambling to operationalize new administrative requirements while bracing for downstream coverage and revenue effects.

• Medicaid work requirements give red states a chance to turn back clock
• How states are planning to implement Medicaid work requirements: survey
• States and hospitals prepare for new administrative tasks as Medicaid work requirements loom
• Billings Gazette: What To Know About Changes Coming to Montana Medicaid
• Montana Public Radio: State Health Officials Consider Cutting Medicaid To Cover Budget Shortfall
• What Do We Know So Far About State Materials & Consumer Outreach on Medicaid Work Reporting Requirements?
• MACPAC Outlines Data Must-Haves For Medicaid Work Reqs Oversight
• Fwd: Regs & Eggs | Ready, set, go: Implementation of Medicaid work requirements is on its way

Tags: #PAYER #HOSPITAL #PATIENT

Hospitals brace for financial strain as Medicaid cuts loom

Hospitals and state governments are actively preparing for financial strain under the One Big Beautiful Bill Act’s Medicaid provisions. Reporting this week spans state aid for distressed safety-net hospitals, hospital playbooks for the coming Medicaid crunch, and analysis of which beneficiaries the cuts will most affect. The combined picture is one of mounting financial pressure on providers serving Medicaid-dependent populations.

• Will the Coming Cuts to Medicaid Spare the ‘Truly Needy’?
• States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
• Flagged hospitals say they are not financially endangered
• ‘Dynamics we haven’t experienced before’: Hospitals absorb costs as patients lose coverage, skip Medicaid
• HMA: Up to 2 million Californians could lose Medi-Cal coverage from federal and state changes
• States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
• ‘We cannot cut our way to success’: Hospitals prep for Medicaid crunch

Tags: #HOSPITAL #PAYER #PATIENT

States move to prop up distressed hospitals as One Big Beautiful Bill Act Medicaid cuts loom

KFF Health News reporter Bernard Wolfson profiles state efforts to shore up financially distressed hospitals — including Martin Luther King Jr. Community Hospital in Los Angeles — as One Big Beautiful Bill Act Medicaid cuts approach. State lawmakers are weighing loans, supplemental payments, and other emergency aid for safety-net institutions facing both the federal cuts and the expected loss of expansion enrollees. The story has been picked up across MedPage Today and the KFF California Weekly Roundup as a feature, signaling a national-level Medicaid stress narrative.

Source(s): (see weekly summary)

Tags: #HOSPITAL #PAYER #PATIENT

Medicaid coverage pressures hit children before HR 1 fully takes effect

Pediatric advocates and policy analysts flagged converging concerns about child Medicaid and CHIP coverage. Georgetown Center for Children and Families documented enrollment drops before HR 1 policies take full effect, alongside analyses of state outreach materials on work reporting requirements and community-based approaches to strengthening children’s health.

• Meeting Families Where They Are: How Medicaid Can Strengthen Children’s Health Through Community Health Workers
• Drop in Child Medicaid and CHIP Enrollment Even Before HR 1 Policies Take Full Effect is Troubling Sign

Tags: #PATIENT #PROVIDER #PAYER

CMS to launch $50 Medicare GLP-1 access pilot starting July

CMS announced a Medicare demonstration that will provide $50 monthly access to GLP-1 weight-loss medications for Medicare beneficiaries starting in July 2026. The pilot is positioned as a short-term bridge to the broader BALANCE model and runs alongside parallel FDA action on GLP-1 compounding. Coverage spans the formal CMS announcement, consumer-facing explainer pieces, and STAT analysis of FDA proposed removal of key GLP-1 ingredients from the compounding list.

• A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
• FDA Proposes Removing Key GLP-1 Ingredients from Compounding List
• CMS News: Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
• Many Medicare Enrollees Can Get GLP-1 Drugs For $50 Starting In July
• Medicare To Launch Pilot GLP-1 Drug Program For $50 A Month

Tags: #DRUG #PAYER #PATIENT

CMMI payment-model watch: GENEROUS, ESRD, and TEAM

Three Center for Medicare and Medicaid Innovation (CMMI) payment models drew analysis this week. KFF examined factors that could shape the GENEROUS Model’s Medicaid drug pricing impact, noting that savings will depend on model details still confidential or uncertain. A new analysis found CMS’s mandatory End-Stage Renal Disease payment model has fallen short of its home-dialysis and transplant goals. A MedCity News commentary argued health systems should approach the Transforming Episode Accountability Model (TEAM) as a transformation catalyst rather than a regulatory burden.

• CMS TEAM Model framed as opportunity for high-performing health systems
• CMS’s mandatory ESRD payment model falls short of home-dialysis and transplant goals
• A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs

Tags: #PROVIDER #PAYER #HOSPITAL

Prior authorization reform gains momentum across CMS, payers, and the AI front

CMS, lawmakers, and at least one major insurer all moved this week on prior authorization reform. CMS Administrator Mehmet Oz published an op-ed framing prior authorization as a top priority while hospitals and electronic health record vendors joined a CMS pledge to streamline the process. UnitedHealthcare announced it will eliminate prior authorization on approximately 30 percent of services by the end of 2026. KFF documented gaps in federal and state consumer protections governing artificial intelligence in claims review and prior authorization.

• UnitedHealthcare cuts prior authorizations by 30%
• UnitedHealthcare to reduce prior auth requirements by 30%
• What’s the latest on prior authorization reform?
• Hospitals, EHR vendors join CMS prior authorization pledge
• Regulation of AI in Prior Authorization and Claims Review: A Look at Federal and State Consumer Protections
• States Curb Insurer AI, Prior Authorizations As Congress Stalls

Tags: #PAYER #PROVIDER #HOSPITAL

Medicare Advantage policy in motion: risk adjustment, FEHB suspension, member shifts, and auto-enrollment

Multiple Medicare Advantage policy threads moved this week. Alignment Healthcare CEO John Kao said on Q1 earnings that he expects CMS to return to its proposed Medicare Advantage risk adjustment changes shortly after the final rate notice, signaling pending CMS regulatory timing on a major MA plan economics lever. Analysts weighed costs and trade-offs of suspending Federal Employee Health Benefits for Medicare Advantage enrollees, Humana reported MA membership gains as rivals exited markets, and CMS signaled it is considering auto-enrolling Medicare-eligible seniors into MA plans.

• Alignment CEO expects short delay for CMS’ proposed risk adjustment changes
• Weighing the costs and trade-offs of suspending FEHB for Medicare Advantage
• Humana Gains Medicare Advantage Members As Rivals Exit Markets
• CMS Mulls Auto-Enrolling Seniors Into Medicare Advantage

Tags: #PAYER #PATIENT

Payer disputes: Medicare Advantage underpayment lawsuit and HIV copay armor probe

Two notable payer policy disputes surfaced this week. Harris Health sued an Elevance subsidiary over alleged Medicare Advantage underpayments. HIV advocates asked regulators in multiple states to probe Highmark’s copay armor policy, alleging it harms patients dependent on copay assistance.

• Harris Health sues Elevance subsidiary over alleged Medicare Advantage underpayments
• HIV Advocates Ask Regulators In Multiple States To Probe Highmark’s ‘Copay Armor’ Policy

Tags: #PAYER #PROVIDER #PATIENT

Rural health policy: cost-based payment extension and Rural Health Transformation Program implementation

A bipartisan group of senators pitched a five-year extension of cost-based payments for some rural hospitals, including a clean version of the proposal. Separately, the National Academy for State Health Policy published guidance on how states can succeed under the Rural Health Transformation Program, the major Medicaid-adjacent rural funding mechanism set up under OBBBA.

• Senators introduce clean extension to cost-based payments for some rural hospitals
• Senators pitch 5-year extension of rural hospital program
• How States Can Succeed Under the Rural Health Transformation Program

Tags: #HOSPITAL #PROVIDER #PAYER

University of Kentucky pitches alternative SDP upper payment limit approach to White House

The University of Kentucky hospital system pitched an alternative State Directed Payment (SDP) upper payment limit framework to White House budget officials. The proposal is part of broader stakeholder engagement as the administration weighs SDP policy changes that could materially affect hospital Medicaid revenue.

Source(s):
KY Hospital System Pitches New SDP Upper Payment Limit Approach To White House

Tags: #HOSPITAL #PAYER

STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs

Medicare is spending far less than projected on the new Alzheimer’s drugs Leqembi and Kisunla, STAT reports. Uptake has been so muted that CMS is not forecasting significant spending on these treatments in 2026 or 2027 — a dramatic shift from two years ago, when Medicare projected billions of dollars in annual Leqembi spending. Neurologists and Medicare experts cite complicated IV administration, extensive imaging requirements, a limited eligible-patient population, and the drugs’ modest benefits against side-effect risks like brain bleeding.

Source(s):
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs

Tags: #DRUG #PROVIDER #PAYER

Food and Drug Administration (FDA)

FDA proposes removing the term ‘gender’ from Title 21 regulations

FDA published a proposed rule that would replace the term ‘gender’ with ‘sex’ throughout Title 21 regulations governing food, drugs, and medical devices. The Federal Register notice, paired with reporting from Inside Health Policy, frames the change as part of a broader administration push on terminology in federal rules.

Source(s):
Modification of Certain Terminology in Title 21
FDA Proposed Rule Would Eliminate Term ‘Gender’ From Regulations

Tags: #DRUG #DEVICE

MAHA advocates push FDA for SSRI black box label; FDA asks for data

Make America Healthy Again advocates are pressing FDA for black box labeling on selective serotonin reuptake inhibitor antidepressants. FDA has responded by asking for supporting data, signaling at least preliminary engagement with the petition rather than outright dismissal. The push connects to HHS Secretary Kennedy’s broader campaign on deprescribing antidepressants.

Source(s):
MAHA Advocates Push For Black Box Labeling On SSRIs, FDA Asks For Data
MAHA advocates push FDA for SSRI black box label; FDA asks for data

Tags: #DRUG #PROVIDER #PATIENT

FDA eyes pilot for prescription-to-over-the-counter drug switches where benefits are substantial

FDA is considering a pilot program to facilitate prescription-to-over-the-counter switches for drugs with substantial public health benefits. The pilot would create a defined pathway for sponsor-initiated Rx-to-OTC applications and could streamline access for high-value categories.

Source(s):
FDA Eyes Pilot For Rx-OTC Drug Switches Where Health Benefits Big

Tags: #DRUG #PATIENT

Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval

Medtronic received FDA approval for its updated Mosaic Neo mitral valve, expanding the company’s mitral portfolio. The approval positions Mosaic Neo against Edwards’ mitral offerings and signals continued competitive activity in surgical mitral valve replacement.

Source(s):
Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval

Tags: #DEVICE

STAT+: What was lost at FDA, one year after DOGE cuts

STAT analyzed the lasting impact of Department of Government Efficiency staffing cuts on FDA one year on, profiling departed senior staff and documenting institutional capacity gaps. The reporting connects to the agency’s broader regulatory environment and signals continued morale and capacity concerns under current leadership.

Source(s):
STAT+: What was lost at the FDA, one year after DOGE cuts

Tags: #DRUG #DEVICE

With Commissioner Under Pressure, F.D.A. Opens Door to Flavored Vapes

The New York Times reports FDA, with Commissioner Makary under pressure, has opened the door to flavored vapes — a policy shift that could allow major tobacco companies to sell flavored e-cigarettes from prime shelf space at thousands of stores. The reporting notes that illicit e-cigarettes have flooded in from China.

Source(s):
With Commissioner Under Pressure, F.D.A. Opens Door to Flavored Vapes

Tags: #DRUG #PATIENT

Department of Health and Human Services (HHS)

TrumpRx and Most Favored Nation drug pricing: $529B projections, expansion plans, and reality checks

White House economists released a Council of Economic Advisers report projecting that President Trump’s Most Favored Nation pricing deals with 17 large pharmaceutical companies will save approximately $529 billion over 10 years, with the administration now pushing to expand the framework. STAT analysis raised methodological questions about the projection. KFF Health News reality-checked the cumulative drug pricing initiatives, finding that while some prices have dropped, many others have risen since the second term began, and examined hidden costs of pharmacy discount coupons under TrumpRx. Bristol Myers Squibb lobbied the White House to reject a CMS combo drug policy in the upcoming IRA negotiation rule. PhRMA launched a seven-figure ad campaign aimed at the US drug discount program, and a Virginia bill to create a Prescription Drug Affordability Board returned to Governor Spanberger’s desk.

• Bill To Create Virginia PDAB Returns To Spanberger’s Desk
• Trump’s Drug Pricing Deals May Save $529 Billion Over 10 Years, White House Says
• WH: Model Projections Show TrumpRx Will Save Tens Of Billions
• BMS asks White House to reject combo drug policy in upcoming IRA rule
• NYT: Trump promised cheaper drugs — some prices dropped, many shot up
• That Discount at the Pharmacy Counter May Pack Hidden Costs
• STAT+: Administration report on most favored nation drug pricing raises new details — and questions
• Touting $529B in savings over 10 years, White House looks to expand MFN deals with pharma
• HIV Advocate Complains WH Bid To Apply TrumpRx To OOP Limits At Odds With Copay Assistance Stance
• PhRMA Launches Seven-Figure Ad Aimed at US Drug Discount Program

Tags: #DRUG #PAYER #PATIENT

Vaccine policy controversies intensify across FDA, CDC, and HHS

Multiple vaccine policy threads escalated this week. The New York Times reported that FDA blocked publication of internal research finding COVID and shingles vaccines safe, prompting a House Energy and Commerce Democratic probe and direct questioning of Secretary Kennedy. Kennedy defended his hepatitis B newborn vaccine rollback at a Cleveland forum. A Massachusetts district court declined the government’s request to stay an order blocking the reconstituted Advisory Committee on Immunization Practices (ACIP) while the appeal proceeds. The MAHA Advisory Committee announced it will meet May 18 with a new chair selected. A separate BMJ study found aluminum vaccine additives not linked to autism or autoimmune conditions, even as the broader administration vaccine-skepticism narrative continued.

• Court Declines To Stay ACIP Case As Appeal Proceeds
• F.D.A. Blocked Publication of Research Finding Covid and Shingles Vaccines Were Safe
• House E&C Democrats probe withholding of vaccine safety studies at CDC and FDA
• FDA stopped publication of studies showing COVID, shingles vaccines were safe
• RFK Jr. Defends Hepatitis B Vaccine Rollback At Cleveland Forum
• Lawmakers Ask Kennedy About Blocked COVID Vaccine Study
• Aluminum In Vaccines Not Linked To Autism, Other Health Problems, Study Finds
• RFK Jr. Defends Decision To Roll Back Hepatitis B Vaccine For Infants
• FDA blocks publication of COVID, shingles vaccine safety studies: NYT
• MAHA Advisory Committee To Meet May 18, Selects Chair

Tags: #DRUG #PATIENT #PROVIDER

RFK Jr. launches HHS effort to encourage antidepressant deprescribing as part of “overmedication” push

HHS Secretary Robert F. Kennedy Jr. announced a new initiative on Monday, May 5, urging clinicians to help wean patients off antidepressants and other psychiatric medications, framing the effort as part of a broader campaign against “overmedication” of Americans. Inside Health Policy and STAT covered the initial announcement; The Hill, NYT, and MedPage Today produced parallel pieces detailing both the deprescribing initiative and the broader HHS strategy. The push is paired with MAHA-led pressure on FDA for an SSRI black box warning.

Source(s):
HHS Unveils Plan To Curb Psychiatric Overprescribing, Encourage Tapering
Kennedy Starts a Push to Help Americans Quit Antidepressants
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
HHS targets ‘overmedication’
HHS Unveils Plan To Curb Psychiatric Overprescribing, Encourage Tapering
RFK Jr. unveils campaign for ‘deprescribing’ antidepressants
RFK Jr. Launches Effort to Encourage Antidepressant Deprescribing
Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting Of Government Support
HHS tackles overmedication

Tags: #PROVIDER #PATIENT #PAYER #DRUG

HHS workforce strains: CDC return-to-office disputes, NIH grant scrutiny, federal worker data, and hiring policy

Multiple threads documented continued strain on the federal health workforce. CDC employees with medical conditions are challenging in-office requirements imposed under the administration, the New York Times reports. NIH employees publicly criticized a Trump-era requirement to scrutinize existing grants, calling it problematic across multiple dimensions. A federal agency was reported pursuing employee health data, drawing alarm from critics. And federal officials remain wary of a skills-based hiring survey after 15 months of attacks on agency hiring practices.

• CDC employees with medical conditions challenge in-office requirement
• ‘Highly problematic for a thousand reasons’: NIH employees criticize Trump-era requirement to scrutinize grants with words related to diversity
• Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
• Feds wary of skills-based hiring survey after 15 months of attacks

Tags: #PROVIDER

KFF MAHA poll: health costs outweigh food and vaccine concerns even among MAHA voters

KFF released its MAHA poll this week, finding that even MAHA voters rank health care affordability concerns above the food, chemical, and vaccine concerns at the center of the MAHA agenda. KFF’s Drew Altman wrote a companion piece arguing there are many MAHAs rather than one monolithic constituency. The Hill and other outlets used the polling to argue Democrats may target MAHA voters on affordability.

Source(s):
Health costs outweigh food, vaccine concerns for MAHA voters: Poll
MAHA Health Concerns Resonate Broadly but Lag Behind Health Care Costs Even for MAHA Voters
KFF Health Tracking Poll: MAHA and the Midterms
Beyond the Data from Drew Altman: There Are Many MAHAs

Tags: #PATIENT #POLICY

Maternal and pregnancy health policy: GAO report, HRSA notices, and bipartisan legislation

Federal action on maternal and pregnancy health spanned oversight, regulatory, and legislative arenas this week. The Government Accountability Office found 242 federal pregnancy and early childhood programs lack performance management. Health Resources and Services Administration released criteria for Maternity Care Health Professional Target Areas and an OMB review notice for Tribal Maternal, Infant, and Early Childhood Home Visiting. Senators Bernie Sanders and Markwayne Moore touted bipartisan solutions to address maternal healthcare gaps.

• GAO: 242 federal pregnancy and early childhood programs lack performance management
• Submission for Office of Management and Budget Review; Tribal Maternal, Infant, and Early Childhood Home Visiting Program: Demographic and Service Utilization Data Report and Performance Measurement Data Report
• Notice of Criteria for Determining Maternity Care Health Professional Target Areas
• Sanders, Moore tout bipartisan solutions to address maternal healthcare gaps

Tags: #PROVIDER #PATIENT

Surgeon General nomination shifts as Saphier replaces Means and CDC director pick proceeds

President Trump pulled the surgeon general nomination of Casey Means and named Fox News contributor Nicole Saphier as the new pick. Deleted social media posts surfaced showing Saphier had criticized Trump and Robert F. Kennedy Jr. health policies. Coverage of the CDC director vacancy continued in parallel.

• Trump pulls surgeon general nomination of Casey Means, names Nicole Saphier as new pick
• Exclusive: Deleted Tweets Reveal New Surgeon General Pick Criticized Trump And RFK Jr. Health Policies
• With A New CDC Director Potentially Chosen, How Can The Role Influence Healthcare?
• New Trump surgeon general pick faces scrutiny over deleted social posts criticizing Trump and RFK

Tags: #POLICY #PATIENT

Foreign-trained physician immigration disruptions and reactions

Two related immigration policy developments affected foreign-trained physicians this week. Reports highlighted that visa program delays threaten placement of hundreds of doctors in underserved areas, while a separate development saw federal officials lift a hold on U.S. immigration applications for doctors specifically, though others remain caught in the freeze. Physician groups responded with cautious praise mixed with continuing concerns.

• Delays in Visa Program Threaten Placement of Hundreds of Doctors in Underserved Areas
• Hold On US Immigration Applications Lifted For Doctors. Others Are Still Waiting
• Physician groups react to visa freeze reversal with praise, questions

Tags: #PROVIDER #PATIENT

ACA marketplace pressure builds: Q1 earnings calls and growing GOP cut tremors

The Affordable Care Act exchanges came under renewed pressure this week. FierceHealthcare’s analysis of Q1 earnings calls found ACA exchanges dominated payer and health system executive commentary, with executives navigating the marketplaces in the wake of GOP-led changes that ended enhanced subsidies. The Hill reported state marketplaces are starting to feel tremors from GOP cuts, with millions dropping coverage and impact growing as One Big Beautiful Bill Act provisions take effect.

• The ACA exchanges dominated Q1 earnings calls. Here’s what payer, health system execs had to say
• Health insurance marketplace feels growing tremors from GOP cuts

Tags: #PAYER #PATIENT #HOSPITAL

White House releases 2026 National Drug Control Strategy; STAT notes inconsistencies with funding actions

The White House released its 2026 National Drug Control Strategy outlining a federal plan focused on overdose prevention, addiction treatment, recovery support, and drug surveillance. The strategy nods to medication-assisted treatment and fentanyl test strips. STAT reports the priorities sit in tension with recent administration funding cuts and policy moves that limit access to those same tools.

Source(s): (see weekly summary)

Tags: #DRUG #PROVIDER #PATIENT

Heard on the Hill

2026 midterms and reconciliation positioning: GOP vision and Democratic affordability push

Health care politics positioning sharpened across both parties this week. Politico Pulse profiled the emerging GOP health care vision through the second Trump term’s policy decisions. The House GOP reconciliation bill may target additional healthcare cuts. Democrats are plotting a health care affordability offensive ahead of the 2026 midterms, eyeing MAHA voters frustrated with rising costs as a potential target audience.

• Democrats seize on MAHA’s growing frustration with GOP
• GOP Reconciliation Bill May Target More Healthcare Cuts
• The GOP health care vision
• Democrats Plot Health Care Affordability Offensive Ahead Of 2026 Midterms

Tags: #POLICY #PAYER #PATIENT

Comer Targets AMA CPT Code System Over Fraud, Rising Costs

House Oversight Chair James Comer is challenging the American Medical Association’s Current Procedural Terminology (CPT) code system, arguing its complexity enables fraud and inflates federal health spending. The intervention reframes a longstanding industry pillar — AMA CPT licensing revenue and payment-rule influence — as a fraud-control issue, opening a path for legislative or regulatory reform of how procedure codes are licensed and adjudicated.

Source(s):
STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
Comer Targets CPT System ‘Complexity,’ Citing Concerns Over Fraud, Rising Health Spending
STAT+: A new attack on AMA’s billing codes
House Oversight chair asks CMS how CPT coding complexity fuels improper billing

Tags: #PROVIDER #PAYER #HOSPITAL

Cancer patient advocates endorse bill to allow reimbursement of trial expenses

Cancer patient advocates have endorsed legislation that would allow reimbursement of clinical trial participation expenses. The bill, profiled in Inside Health Policy, addresses long-standing concerns about financial barriers that limit trial enrollment.

Source(s):
Cancer Patient Advocates Endorse Bill To Allow Reimbursement Of Trial Expenses

Tags: #PATIENT

SNAP and the farm bill’s fate

Senate Agriculture Democrats are pushing for changes to the Supplemental Nutrition Assistance Program (SNAP) cost-sharing framework — enacted last summer as part of the One Big Beautiful Bill Act — to be included in the chamber’s farm bill, POLITICO Morning Agriculture reports. The law requires states with SNAP error rates of 6% or higher to split program costs with the federal government, a provision some state officials say could leave them unable to run SNAP at full capacity. Sen. Tina Smith (D-Minn.) and Senate Agriculture ranking member Amy Klobuchar (D-Minn.) have called for relief on the cost shifts, with Klobuchar’s committee Democrats committing to delaying the new SNAP cost shifts so all states are treated equally. The Senate faces a tight timeline to negotiate, pass, and deliver a farm bill before the August recess, with banking measures and the NDAA competing for floor time. The newsletter also covered USDA’s reorganization of Food and Nutrition Service employees (the National WIC Association warned this could disrupt state WIC operations, with 30% of FNS staff having departed in the past year) and a $32M ARS reduction at the Beltsville Agricultural Research Center eliminating 9 research projects and reducing funding for 8 others.

Source(s):
SNAP and the farm bill’s fate

Tags: #PATIENT #PAYER

Congress.gov Committee Schedule Alert

Congress is scheduled for 46 committee meetings the week of May 11-17, 2026. Notable health-relevant hearings: Senate Appropriations Agriculture/FDA on the FDA FY2027 budget request (Wednesday May 13); House Education/Workforce on Department of Education policies (Thursday); Senate Homeland Security on a COVID whistleblower; and Veterans Affairs markups. Several FY2027 budget hearings are scheduled across non-health departments (Navy, Army, HUD, EPA, Interior, GSA, NRC, USDA, Forest Service). Tuesday May 12 includes Senate Special Aging on the Sandwich Generation. Senate Judiciary will hold open business meetings and judicial nomination work.

Source(s): (see weekly summary)

Tags: #ALL

Notable Notes

Edwards Resilia tissue: Kevin Accola, MD on what ten-year COMMENCE data mean for valve durability

Cardiovascular Business interviewed Kevin Accola, MD on the implications of the ten-year COMMENCE aortic trial data released by Edwards Lifesciences supporting long-term durability and sustained performance of its proprietary Resilia tissue platform. The data set underpins Edwards’ broader surgical and transcatheter valve durability positioning.

Source(s):
Resilia tissue developed by Edwards Lifesciences associated with long-term durability

Tags: #DEVICE #PROVIDER

TAVR vs SAVR decision-making in focus: joint statement, outcomes prediction, and guideline updates

Cardiovascular Business and the American Association for Thoracic Surgery covered a confluence of TAVR-versus-SAVR decision-making material this week. A new joint statement from cardiologists and heart surgeons emphasized the care that goes into each procedure choice. Researchers continue developing improved approaches to predict individual patient outcomes, and presentations at the AATS 106th Annual Meeting reviewed how expert guidelines have shaped TAVR-versus-SAVR decisions over time. The Week in Review newsletter from Cardiovascular Business led with TAVR/SAVR coverage alongside cardiac CT trends and FDA Class I recall news.

• New ways to predict TAVR outcomes for individual heart patients
• TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision
• TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision
• New ways to predict TAVR outcomes for individual heart patients
• How expert guidelines have influenced TAVR vs. SAVR decisions

Tags: #DEVICE #PROVIDER

Medtronic TAVR Low Risk Bicuspid Study status update

Medtronic’s pivotal study of TAVR in low-risk patients with bicuspid aortic valve anatomy is now active but no longer recruiting (NCT03635424). The trial is designed to support label expansion of Medtronic’s Evolut platform into the bicuspid patient population.

Source(s):
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Tags: #DEVICE #PROVIDER

HeartBeam expands US commercial presence through concierge-practice partnership

HeartBeam announced commercial expansion across four US markets through addition of a Premier Concierge Practice partner. HeartBeam develops 12-lead synthesis cardiac monitoring technology and the expansion deepens its physician-channel footprint.

Source(s):
HeartBeam expands US commercial presence with new concierge-practice partnership

Tags: #DEVICE #PROVIDER

Nearly 8 in 10 employers say GLP-1 coverage is driving up benefit costs: Business Group on Health

A new Business Group on Health survey reports that nearly 80% of large employers say GLP-1 medication coverage is significantly driving up their benefit costs. Healthcare Dive and Fierce Healthcare both covered the survey. The findings land as CMS announces its $50/month Medicare GLP-1 demonstration and as employer benefit design conversations increasingly center on GLP-1 cost containment.

Source(s):
Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
GLP-1 coverage costs pressure employers and Medicare plans in 2026
GLP-1s, Specialty Spend, and a 9% Cost Surge: Why Employers Must Rethink Primary Care Now

Tags: #DRUG #PAYER #HOSPITAL

Pennsylvania sues Character.AI over chatbot allegedly impersonating licensed clinicians

Pennsylvania Attorney General Dave Sunday filed suit against Character.AI, alleging the platform’s chatbots presented themselves as licensed medical and mental health professionals to users. The action positions state attorneys general at the front of AI consumer protection enforcement in healthcare contexts.

Source(s):
Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors

Tags: #PATIENT

A Single Infusion Could Suppress H.I.V. for Years, Study Suggests

The New York Times reports a small study (presented this week) suggests a single infusion of immunotherapy could suppress HIV for years — a treatment approach that has already cured some blood cancers.

Source(s):
A Single Infusion Could Suppress H.I.V. for Years, Study Suggests

Tags: #DRUG #PROVIDER #PATIENT